Connect Sign In
ARUP’s new assay, Influenza A (H5) Virus by Qualitative NAAT (ARUP test number 3018970), will expand the national capacity to detect the current outbreak of highly pathogenic avian influenza A (H5N1). |
January 3, 2025 | ARUP Offers New Assay To Detect Influenza A (H5) Virus ARUP has launched a new assay for the detection and subtyping of influenza A (H5) virus, which will expand the national capacity to detect the current outbreak of highly pathogenic avian influenza A (H5N1). |
ARUP Laboratories and Augurex Life Sciences Corp. are partnering to incorporate a 14-3-3η test that will aid in the early detection and management of rheumatoid arthritis. |
October 21, 2024 | Augurex Announces Agreement With ARUP To Expand Access to Advanced Rheumatoid Arthritis Diagnosis ARUP Laboratories is partnering with Augurex Life Sciences Corp. to include the 14-3-3η test in the ARUP test menu to enhance the early detection of rheumatoid arthritis. |
Digitally colorized transmission electron microscopic image of avian influenza A (H5N1) virus particles (in gold), grown in Madin-Darby canine kidney (MDCK) epithelial cells (in green). |
September 13, 2024 | ARUP Awarded CDC Contract for Bird Flu Test Development ARUP has been awarded a CDC contract for avian influenza A (H5N1) test development, which recognizes our expertise and experience with assay development and our desire to serve public health needs. |
The research grant is named in honor of retired ARUP CEO Sherrie Perkins, MD, PhD, whose leadership laid the groundwork for ARUP’s increased focus on innovation. |
July 30, 2024 | New ARUP Laboratories’ Grant Will Fund Innovative Research to Advance Laboratory Medicine The new Sherrie Perkins Research and Innovation Collaboration Grant, designed to foster collaboration in healthcare, will fund cutting-edge research in lab medicine that could impact patient care. |
ARUP Laboratories has filed a declaration supporting a lawsuit against the FDA brought by the American Clinical Laboratory Association. |
May 30, 2024 | ARUP Files Declaration to Support Lawsuit Challenging the FDA's Rule to Regulate Lab-Developed Tests ARUP’s declaration amplifies the lawsuit’s claims that the FDA does not have legal authority over laboratory testing services and that regulating these services is unreasonable. |
ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs. |
April 29, 2024 | ARUP Statement on FDA Final Rule to Regulate Laboratory-Developed Tests as Medical Devices ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs. |
ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ We accelerate the development and adoption of cutting-edge diagnostic and prognostic technologies advancing patient care through groundbreaking science and engineering. The Sherrie Perkins Research and Innovation Collaboration Grant The Sherrie Perkins Research and Innovation Collaboration Grant funds cutting-edge research in laboratory medicine.
Press Releases
Live Chat